Q: We hear there are some exciting new releases on the horizon for NCI, can you share a little about what is in the works?
A: NCI has received FDA clearance for the novel cardiac monitoring wearable patch named Liba 3. This new approach to remote cardiac monitoring will replace 30-year-old technology widely used today.
- Remote cardiac monitoring wearables traditionally send short bursts of information to a physician monitoring a patient’s cardiac health through wireless patches the patient wears on their chest. There have been issues with data loss and missed arrhythmias in the past.
- The Liba 3 patch has been designed to make cardiac monitoring much more easily wearable. The integrated technology accesses the Cloud to bring immediate, secure monitoring information to a physician.
Q: When will this exciting new technology be rolled out?
A: NCI is very excited to partner with one or more industry leaders in technology and distribution to launch the Liba 3 in the last quarter of 2020.
Q: Where do you see NCI in the coming 1 – 5 years?
A: We would like to build NCI into a very attractive acquisition candidate for one of the large companies who are currently trying to compete in this space, which has not seen marked innovation in the last 30+ years. An acquisition is certainly our overall goal.
At TGG we are proud to partner with companies like NCI who are innovating, creating a better tomorrow and using the clear and accurate financials we can provide to succeed in their industries.